Leukopaks and apheresis products: nothing is publicly priced, and the recallable donor is the thing to ask for

Start with the honest statement, because it is the first thing a buyer needs to know and the last thing anyone tells them.

No supplier of human blood, leukopak or apheresis products publishes a price. HemaCare, iSpecimen and Sanguine were all checked on 2026-09-01. Two of the three block automated retrieval entirely. All three route to a quote. We do not estimate one, and any page that gives you a per-leukopak figure without naming the supplier, the cohort and the date is guessing.

That opacity has a practical consequence beyond inconvenience: you cannot compare cohort feasibility across vendors without opening three parallel sales conversations. By the time you have comparable numbers you have spent weeks. So the leverage is in specifying the cohort well enough that the three conversations can run simultaneously and produce answers to the same question.

The three supplier models and what actually separates them

Read the differentiator column, because that is where the choice actually gets made. These are not three vendors selling the same thing at different prices. They are three different answers to different problems.

The recallable donor: the capability first-time buyers do not know to ask for

HemaCare operates apheresis collection with a recallable donor programme, repeat draws from the same individual.

For a longitudinal design that removes donor as a variable in a way no inventory purchase can. If your experiment compares a baseline against a treated or later state, and your baseline and follow-up samples come from different people, donor variation sits on top of your effect. If they come from the same person, it does not.

This is the single most valuable capability in the category and it is almost never requested by first-time buyers, because it does not occur to them that a supplier can go back to a specific donor months later. It can. Ask for it by name.

Two caveats to plan for:

• It has a lead time. A recall is a scheduled collection from a specific consented individual, not a pick from inventory. It cannot be compressed at the end of a study.
• It requires the consent scope to cover it. A recallable programme is built on a consent that contemplates repeat contact. That is a different document from a one-off collection consent, and it is a reason to raise the requirement at the start of a programme rather than after the first timepoint.

Inventory or prospective collection: one question decides it

The decision rule that determines which supplier model you should be talking to:

Is the pre-analytical variable part of your experiment?

If time to freeze, anticoagulant choice, tube type or processing method is a factor you are measuring or must control, buy prospective collection and fund the recruitment. If it is not, standing inventory is the correct answer and prospective collection is money wasted.

The literature is unambiguous that these variables matter when they matter. Work optimising PBMC cryopreservation and utilisation for ImmunoSpot analysis of antigen-specific B cells (PMC12299797) documents how the freezing protocol affects downstream functional readout. Real-time metabolic profiling of PBMCs has been reported with explicit methodological considerations (PMC12605198), which is a statement that the handling is entangled with the measurement. And the impact of pre-analytical variables on cell-free DNA analysis from blood (PMC11111958) is documented for molecular endpoints specifically.

But note the symmetry. Those same papers imply that for endpoints where the handling is not the variable, well-processed inventory material is entirely adequate, and inventory is faster and cheaper. Funding prospective collection when you did not need it is the most common avoidable overspend in this category. A supplier who sells you a prospective collection without first asking what your endpoint is has not done their job.

Fresh or cryopreserved

The second decision that changes both supplier shortlist and price.

Fresh material has a hard clock. It has to be collected, shipped and received inside a window your assay tolerates, which constrains collection geography, shipping route and, practically, which day of the week you can start. It is the correct choice when the assay requires cells that have never been frozen, and the cost is schedule fragility.

Cryopreserved material decouples collection from use, allows a single donor’s material to be split across timepoints and sites, and is what makes multi-site studies feasible. The cost is the freeze-thaw itself, which is a real perturbation and which the cryopreservation literature above addresses directly.

The practical question to ask suppliers: which one is your assay validated in? A protocol validated on fresh PBMCs run on cryopreserved material is a protocol change, and vice versa. Deciding this before the enquiry means the quotes come back comparable.

Related, and easy to underestimate: the cold chain itself is a line item. Fresh material shipping to a deadline and cryopreserved material in a dry shipper have very different costs and different receiving requirements. Both are covered in shipping and cold chain costs and shipping live cells and tissue.

Leukopak, mobilised leukopak, or PBMC

Three products that get conflated in enquiries and are not the same purchase.

PBMC. Isolated mononuclear cells, typically supplied as a defined cell count per vial. The finished product for most immunology work. Convenient and the most expensive per cell.

Leukopak. An enriched leukocyte apheresis product, substantially more cells than a standard blood draw yields, supplied as a pack rather than a counted vial. The correct purchase when you need large cell numbers or intend to isolate subsets yourself.

Mobilised leukopak. Collected from a donor treated to mobilise haematopoietic progenitors into the circulation, so the product is enriched for CD34-positive cells. A different product for a different purpose, and mobilisation is a medical intervention on a donor, which is why it is a separate and more constrained offering.

Isolated immune subsets. T cells, NK cells, monocytes and others, isolated by the supplier. You pay for the isolation and you get consistency and time back.

The choice hinges on whether you want to do the isolation. Cell therapy manufacturing work, for example the manufacturing and preclinical validation of CAR T cells targeting ICAM-1 (PMC6650612), starts from apheresis material and performs its own selection, because the selection is part of the process being developed. A discovery immunology group measuring a response in a defined subset usually should not be building an isolation workflow to get there.

Ask for yield per unit, not just the product name. A leukopak’s value is its cell count, and that number is donor-dependent. Get the specification and get the range.

HLA typing, disease state and cohort definition

The fields that turn a general enquiry into a quotable one.

HLA type, where the experiment depends on it, antigen presentation, tetramer work, allogeneic matching. This narrows the donor pool sharply and is one of the main drivers of both price and lead time. State whether it is mandatory or preferred.

Disease state. Sanguine catalogues disease-specific fluids including rheumatoid arthritis and osteoarthritis synovial fluid, which illustrates how far the specification can go beyond “PBMCs from a patient”. If a disease cohort is the requirement, direct-to-patient recruitment models are built for exactly that; a marketplace over standing inventory may or may not hold it.

Demographics. Age, sex, ethnicity, and any comorbidity or medication exclusion. Every mandatory field narrows the pool. Separate the mandatory from the preferred explicitly in the enquiry, because a supplier who treats a preference as a requirement will come back with a longer lead time and a higher price than necessary, and a supplier who treats a requirement as a preference will send you the wrong cohort.

Number of unique donors, stated separately from total volume or cell count. These are two different numbers and buyers routinely supply only one. Twenty million PBMCs from one donor and twenty million from ten donors are different products at different prices for different experiments.

What the marketplace model is actually selling

Worth being explicit, because it is easy to misread iSpecimen’s proposition as merely a larger catalogue.

The claim is contractual rather than biological: one contract covering hundreds of providers, with the marketplace managing contracting and compliance across every contributor site. Anyone who has assembled a multi-institution cohort knows that the paperwork rather than the material sets the schedule. Negotiating material transfer agreements with eleven hospitals individually is a multi-month exercise before a single tube moves.

So the marketplace is not primarily competing on price or on biology. It is competing on the elimination of contracting overhead. Whether that is worth anything to you depends entirely on whether your alternative involved contracting with multiple institutions. For a single-cohort purchase from one source it may add little. For a diverse multi-source cohort it can be the difference between a feasible study and an abandoned one.

QC checklist

• Donor consent documentation with the scope stated against your intended use, including commercial use and genomic analysis if either applies.
• IRB and ethics documentation, with the protocol identifier for prospectively collected material, and confirmation of whether your institution requires its own determination.
• Serology and infectious disease screening, with agents named per the supplier’s protocol.
• Viability and cell count at release, with the assay and the time point stated.
• Yield per unit for leukopaks, with the expected range rather than a single figure.
• Chain-of-custody and collection-to-processing time record, as recorded numbers per unit.
• Anticoagulant and tube type used, documented per unit.
• Cryopreservation protocol, freezing medium, rate, storage temperature, where the product is cryopreserved.
• Cold chain documentation and temperature logging for the shipment.
• HLA typing results where typed, with the resolution level stated.
• Confirmation of whether multiple units came from the same donor, where that matters to your design.
• For recallable programmes: written confirmation that the consent covers repeat contact, and the lead time for a recall draw.

Specification checklist for a blood or apheresis quote

• Product class: whole blood, PBMC, leukopak, mobilised leukopak, bone marrow aspirate, or a named isolated immune subset. Use the correct term; they are different products.
• Fresh or cryopreserved, and for fresh, the maximum acceptable time from draw to receipt.
• Cell yield or volume per unit, and the number of unique donors, as two separate numbers.
• Donor demographics, HLA type and disease state, with mandatory and preferred fields separated.
• Recallable donor requirement for longitudinal or repeat-draw designs, raised at the start of the programme.
• Anticoagulant, tube type and processing window, specified where the pre-analytical variable is part of the experiment and left to the supplier where it is not.
• Banked inventory or prospective collection under IRB, decided against that same question.
• Consent scope required, listed explicitly.
• Matched clinical annotation or serology, field by field.
• Delivery schedule, including which weekday fresh material can be received, and the shelf life on arrival.
• Whether the same donor’s material must cover multiple timepoints or sites, which is a cryopreservation and reservation question as much as a collection one.

Where to go next

The datasheet, unit, lead time and QC scope, is at human-blood-and-apheresis-products. For solid tissue and other consented human material, human biospecimens covers the same consent and chain-of-custody ground. The supplier landscape, including which vendors block verification, is in biospecimen suppliers, and the cold chain costs are in shipping and cold chain costs.

How we can help

In a category where nobody publishes a price and two of three principal suppliers block automated retrieval, the useful work is writing one cohort specification precise enough to send to all of them at once, so the quotes are comparable when they come back rather than three descriptions of three different studies.

Tell us the product class, the cohort definition with mandatory and preferred fields separated, the number of unique donors, whether the pre-analytical window is part of your experiment, and whether the design needs repeat draws from the same person. We will put the same enquiry to each supplier, ask for yield ranges rather than single figures, obtain the consent scope in writing, and tell you where prospective collection is being sold to you that standing inventory would satisfy.